MIRA Pharmaceuticals is a clinical-stage pharmaceutical company developing three oral drug candidates targeting neuropathic pain, inflammatory pain, obesity, and addiction. MIRA has no approved products and no revenue. Its most advanced program, Ketamir-2, is an oral NMDA receptor modulator designed to deliver ketamine-like pain relief without the dissociative side effects associated with ketamine. Ketamir-2 has completed Phase 1 with no serious adverse events and is targeting a Phase 2a trial in chemotherapy-induced peripheral neuropathy — a condition with no currently FDA-approved treatments — in the first half of 2026. MIRA-55 is a preclinical oral cannabinoid analog designed to preferentially activate CB2 receptors for anti-inflammatory and analgesic effects, while minimizing the psychoactive CB1 activation associated with cannabis. SKNY-1, acquired via MIRA's purchase of SKNY Pharmaceuticals in 2025, is the earliest-stage program — preclinical only — and targets obesity and nicotine addiction by modulating CB1, CB2, and MAO-B pathways. MIRA holds exclusive U.S., Canada, and Mexico rights to all three compounds, licensed from MIRALOGX, a related party. The company operates with two part-time employees and relies on outside consultants and contract research organizations. MIRA funds operations entirely through capital raises, with the goal of advancing programs to clinical proof-of-concept and then licensing or partnering with larger pharmaceutical companies.